Precision medicine solutions
for healthcare institutions, pharmaceutical companies and academic researchers
A unique dedicated portal with high-value scientific materials and major updates in the field of oncology, genetics and precision medicine.
Case of the Month
March: 42-year-old male with a metastatic colorectal cancer
2 min reading
Published Mar 18th
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance to the adjuvant therapy. Therefore a genomic profile of the tumor has been performed using the OncoDEEP solution.
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.
Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory. Gosselies, Belgium and Paris, France,...
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services
In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...
February: 40-year-old male with a stage IV glioma cancer
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...
Advancing personalized cancer treatment: Webinar Replay
Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar
Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine
Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...
January: 45-year-old male with an intrahepatic cholangiocarcinoma
We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers
Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...
OncoDNA laboratory has received the CAP accreditation
Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...
They trust us, we trust them
Years of trust, countless tests run, genes, and trials explored.
Our mission
OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.